Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
8 min read
ARV-6723 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
7 August 2026
ARV-6723: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Venthera, Inc. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
7 August 2026
Venthera, Inc. BD opportunity scan covering pipeline ownership, stage, evidence package, IP risk, deal precedent, financial signals and outreach rationale using PatSnap MCP.
Latest Hotspot
8 min read
qed THERAPEUTICS Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
7 August 2026
qed THERAPEUTICS BD opportunity scan covering pipeline ownership, stage, evidence package, IP risk, deal precedent, financial signals and outreach rationale using PatSnap MCP.
Latest Hotspot
8 min read
Retinagenix Therapeutics, Inc. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
7 August 2026
Retinagenix Therapeutics, Inc. BD opportunity scan covering pipeline ownership, stage, evidence package, IP risk, deal precedent, financial signals and outreach rationale using PatSnap MCP.
8 min read
METI-101 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
7 August 2026
METI-101: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
LVT-001 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
7 August 2026
LVT-001: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Innova Therapeutics Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
7 August 2026
Innova Therapeutics BD opportunity scan covering pipeline ownership, stage, evidence package, IP risk, deal precedent, financial signals and outreach rationale using PatSnap MCP.
![[68Ga]Ga-DOTA-TOC Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go](https://synapse-static-patsnap-com.libproxy1.nus.edu.sg/strapi-static/Blog_cover_12_7f0c44f64f.jpg)
8 min read
[68Ga]Ga-DOTA-TOC Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
7 August 2026
[68Ga]Ga-DOTA-TOC: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
Mesothelin and Claudin 18.2 Dual-Target CAR-T(Essen Biotech) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
7 August 2026
Mesothelin and Claudin 18.2 Dual-Target CAR-T(Essen Biotech): Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP.
8 min read
LNP.UCD.ABE Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
7 August 2026
LNP.UCD.ABE: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
ANOC-003 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
7 August 2026
ANOC-003: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
AAV2-8-HLP-FVIII-V3(University College London) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
7 August 2026
AAV2-8-HLP-FVIII-V3(University College London): Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals.